Biolinerx Ltd.'s chief business officer, David Malek, told BioWorld Today that the phase III trial with stem cell mobilizer BL-8040 likely will not be a head-to-head trial with approved Mozobil (plerixafor, Sanofi SA), but the candidate's affinity to the same target, CXCR4, is "several orders of magnitude stronger," and could yield data regarded as superior.